Aminophenols
Medchemexpress LLC Ozanimod hydrochloride | 1618636-37-5 | 98.1% | 25MG
Ozanimod hydrochloride | 1618636-37-5 | 98.1% | 25MG
Medchemexpress LLC CX-6258 hydrochloride hydrate | 1353858-99-7 | 99.23% | 516.42 | 100 MG
CX-6258 hydrochloride hydrate is a potent and kinase-selective pan-Pim kinases inhibitor, with IC50s of 5 nM, 25 nM, and 16 nM for Pim-1, Pim-2, and Pim-3, respectively. It is intended for research use only and not for sale to patients.
- Potent and kinase selective pan-Pim kinases inhibitor.
- Inhibits the phosphorylation of pro-survival proteins Bad and 4E-BP1 at specific Pim kinase sites (S112, S65, and T37/46 respectively).
- Diminishes steady-state levels of ectopic NKX3.1 in PC3 cells.
- Reduces NKX3.1 half-life.
- Exhibits robust in vivo efficacy in two Pim kinases driven tumor models, showing dose-dependent tumor growth inhibition (TGI) of 45% at 50 mg/kg and 75% at 100 mg/kg in MV-4-11 xenograft models in nude mice.
=O | 1g | 205380804](https://assets.fishersci.com/TFS-Assets/CCG/product-images/502186108.JPG-250.jpg)
eMolecules 13073-29-5 | 2-Methyl-6-nitrophenol | Combi-Blocks | MFCD00031116 | 153.137 | C7H7NO3 | 98.000 | Cc1cccc(c1O)[N+]([O-])=O | 1g | 205380804
2-Methyl-6-nitrophenol | Combi-Blocks | 13073-29-5 | MFCD00031116 | 153.137 | C7H7NO3 | 98.000 | Cc1cccc(c1O)[N+]([O-])=O | 1g | 205380804
Medchemexpress LLC Ozanimod hydrochloride | 1618636-37-5 | 98.1% | 50MG
Ozanimod hydrochloride | 1618636-37-5 | 98.1% | 50MG
Medchemexpress LLC CPI-455 hydrochloride | 2095432-28-1 | 100.0% | 314.77 g/mol | C16H15ClN4O | 5 MG
CPI-455 hydrochloride is the hydrochloride salt of a potent, selective pan-KDM5 histone demethylase inhibitor used in biochemical and cellular epigenetic research. It inhibits KDM5A with an IC50 of ≈10 nM, elevates global H3K4 trimethylation, and has been applied in studies of drug-tolerant persister cancer cells.
- Potent pan-KDM5 inhibitor (IC50 ≈ 10 nM for KDM5A).
- Elevates global H3K4 trimethylation in cellular assays.
- Hydrochloride salt form for enhanced stability and handling.
- Molecular formula C16H15ClN4O; molecular weight 314.77 g/mol.
- CAS number 2095432-28-1 for unambiguous identification.
- High purity (listed as 99.95%), suitable for research applications.
- Soluble in DMSO; water insoluble.
- Available in small laboratory pack sizes for screening and mechanistic studies.
Medchemexpress LLC CX-6258 hydrochloride | 1353859-00-3 | 99.0% | 498.40 | 100 MG
CX-6258 hydrochloride is a potent and kinase selective pan-Pim kinases inhibitor, with IC50s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively. For research use only. We do not sell to patients.
- Potent and kinase selective pan-Pim kinases inhibitor.
- Inhibits phosphorylation of pro-survival proteins Bad and 4E-BP1 at specific Pim kinase sites.
- Exhibits robust in vivo efficacy in Pim kinases driven tumor models.
Medchemexpress LLC LY266097 hydrochloride | 172895-39-5 | 99.6% | 407.33 g/mol | C21H24Cl2N2O2 | 1 ML
A selective 5-HT2B receptor antagonist supplied as the hydrochloride salt for laboratory research applications. It is used in vitro and in vivo to study 5-HT2B-mediated signaling and neurotransmitter modulation. For research use only.
- High purity, 99.6%.
- Molecular weight 407.33 g/mol.
- Molecular formula C21H24Cl2N2O2.
- Available as 10 mM 1 mL solution in DMSO or as solid vials (5-100 mg).
- Recommended storage: sealed at -80°C up to 6 months or at -20°C up to 1 month.
Medchemexpress LLC L-NAME hydrochloride (NG-Nitroarginine methyl ester hydrochloride) | 51298-62-5 | 99.9% | 269.69 | 500 MG
L-NAME hydrochloride is a nitric oxide synthase (NOS) inhibitor with an IC50 of 70 μM. It acts as a precursor to the more potent NOS inhibitor L-NOARG (IC50 of 1.4 μM), making it valuable in studies of L-arginine analogues that inhibit NOS activity. Its efficacy can increase with prolonged incubation at neutral or alkaline pH, correlating with its hydrolysis to L-NOARG. This compound is also used to induce hypertension and preeclampsia models in animal studies.
- Inhibits NOS with an IC50 of 70 μM.
- Precursor to NOS inhibitor L-NOARG.
- Used to induce hypertension and preeclampsia models in animal studies.
- Appearance: solid, white to off-white.
- Storage: -20°C, sealed, away from moisture.
- In solvent: -80°C for 6 months; -20°C for 1 month.
Medchemexpress LLC AP14145 hydrochloride | 2387505-59-9 | 98.3% | 5 MG
AP14145 hydrochloride is a hydrochloride salt of a small-molecule negative allosteric modulator of KCa2 (SK) channels. It shows in vitro potency near 1.1 μM for KCa2.2 (SK2) and KCa2.3 (SK3) and has demonstrated prolongation of atrial effective refractory period and antiarrhythmic effects in preclinical models. Supplied as a 5 MG vial with reported purity of 98.3%.
- Negative allosteric modulator of KCa2 (SK) channels
- In vitro potency around 1.1 μM for SK2 and SK3
- Demonstrated atrial electrophysiology effects in vivo
- Hydrochloride salt form for improved handling
- High reported purity (98.3%)
Medchemexpress LLC SR9011 hydrochloride | 2070014-94-5 | 99.0% | 515.50 | 2 MG
SR9011 hydrochloride is a potent REV-ERBα/β agonist (IC50s: 790 nM for REV-ERBα, 560 nM for REV-ERBβ). It significantly increases REV-ERB-dependent repressor activity and suppresses transcription via full-length REV-ERBα. The compound inhibits BMAL1 mRNA expression in HepG2 cells and suppresses breast cancer cell proliferation by halting the cell cycle before M phase. In mice, SR9011 suppresses REV-ERB responsive genes and temporarily reduces locomotor activity during the dark phase.
- Potent REV-ERBα/β agonist.
- Increases REV-ERB-dependent repressor activity.
- Suppresses transcription via full-length REV-ERBα.
- Inhibits BMAL1 mRNA expression in HepG2 cells.
- Suppresses breast cancer cell proliferation.
- Pauses cell cycle prior to M phase, increasing G0/G1 phase cells.
- Suppresses REV-ERB responsive genes in mice.
- Reduces locomotor activity in mice under dark conditions.
Medchemexpress LLC Metixene hydrochloride hydrate | 7081-40-5 | ≥95.0% | 5MG
Metixene hydrochloride hydrate | 7081-40-5 | ≥95.0% | 5MG
Medchemexpress LLC ZZW-115 hydrochloride | 10122-45-9 | 98.09% | 573.97 | 25 MG
ZZW-115 hydrochloride is a potent NUPR1 inhibitor with a Kd of 2.1 μM. It induces tumor cell death through necroptosis and apoptosis, demonstrating anticancer activity.
- Effective in killing cancer cells with IC50 values ranging from 0.84 μM to 4.93 μM in various cell lines in vitro.
- Induces pancreatic cell death by necrosis and apoptosis, leading to decreased ATP production and increased ROS overproduction.
- Causes higher LDH release and greater caspase 3/7 activity in a concentration-dependent manner.
- Inhibits the growth of pancreatic xenografted tumors in mice when administered at 0.5-5 mg/kg daily for 30 days via injection.
- Dosage of 5 mg/kg for 30 days resulted in almost unmeasurable tumor sizes in some cases of C57BL/6 mice.
- Caused tumors to progressively decrease and almost disappear by the end of treatment in nude mice xenografted with MiaPaCa-2 cells at a 5 mg/kg dose.
Medchemexpress LLC Ly294002 (hydrochloride) | 934389-88-5 | MFCD00270881 | 99.9% | 343.80 g/mol | C19H18ClNO3 | 100 MG
LY294002 hydrochloride is the hydrochloride salt of LY294002, a broad-spectrum phosphoinositide 3-kinase (PI3K) inhibitor that also shows activity against CK2 and DNA-PK. Supplied for research use in powder and solution formats, it is used to probe PI3K signaling, apoptosis, and related kinase pathways. CAS 934389-88-5; molecular weight 343.80 g/mol; high purity suitable for biochemical and cell-based assays.
- Potent PI3K inhibitor useful for signaling studies.
- Also inhibits CK2 and DNA-PK, enabling broader kinase pathway interrogation.
- Available as powder and as DMSO solution for flexible dosing.
- High purity suitable for biochemical and cell-based assays.
- Stable when stored sealed at 4°C, away from moisture.
- Widely used in oncology and cell signaling research applications.
Medchemexpress LLC LCKLSL hydrochloride | 98.1% | 712.34 | 1 MG
LCKLSL hydrochloride is an N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. It potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2, inhibits the generation of plasmin, and has anti-angiogenic roles. In human retinal microvascular endothelial cells (RMVECs), LCKLSL inhibits plasmin generation and suppresses VEGF-induced tPA activity under hypoxic conditions. Application in in vivo models of angiogenesis demonstrates suppression of angiogenic responses.
- Competitive annexin A2 (AnxA2) inhibitor
- Inhibits binding of tissue plasminogen activator (tPA) to AnxA2
- Inhibits generation of plasmin
- Anti-angiogenic roles
- Decreases vascular length in vivo